好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Lower-Sodium Oxybate Dose Titration and Transition From Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy
Sleep
Sleep Posters (7:00 AM-5:00 PM)
013

Evaluate dose adjustment of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate, LXB; XywavTM; previously designated as JZP-258) during titration in a double-blind, placebo-controlled, randomized withdrawal study.

Sodium oxybate (SXB; Xyrem®) is a standard of care for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy. LXB is an oxybate medication with 92% less sodium than SXB.
At study entry, participants were taking SXB only, SXB+other anticataplectics, anticataplectics other than SXB, or were cataplexy treatment–naive. LXB treatment began during a 12-week, open-label optimized treatment and titration period. Participants taking SXB only or SXB+other anticataplectics transitioned to LXB at the same gram-for-gram dose as SXB and adjusted to an efficacious and tolerable (optimized) dose during weeks 3–12. Participants taking other anticataplectics or who were anticataplectic-naive initiated LXB at 4.5 g/night and titrated to an optimized dose at ≤1.5 g/night/week (maximum total dose, 9 g/night). A 2-week stable-dose period (SDP) and 2-week, double-blind, randomized withdrawal period followed.
Most participants (91%) taking SXB at study entry had no dose adjustment or adjustments within 1 titration step (±1.5 g/night). The median (range) number of adjustments was 0.0 (0–8) in participants taking SXB at study entry and 3.0 (0–7) in participants not taking SXB at study entry. Total nightly stable LXB dose (median [range]) was higher in participants taking SXB at study entry (SXB-only, 7.5 g [4.5–9.0], n=41; SXB+other anticataplectics, 9.0 g [6.0–9.0], n=14) compared with those not taking SXB (other anticataplectics, 7.5 g [4.5–9.0], n=21; anticataplectic-naive, 7.0 g [3.0–9.0], n=58), with fewer dose adjustments made.
Most participants taking SXB at study entry transitioned to LXB at the same dose or within 1 titration step. Participants not previously taking SXB achieved an individually optimized dose of LXB after a median of 3 adjustments.
Authors/Disclosures
Nancy R. Foldvary-Schaefer, DO, FAAN (Cleveland Clinic)
PRESENTER 		Dr. Foldvary-Schaefer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care.
Richard K. Bogan, MD (SleepMed) Dr. Bogan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony. Dr. Bogan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. Dr. Bogan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Bogan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel. Dr. Bogan has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Noctrix. Dr. Bogan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Harmony. Dr. Bogan has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Jazz. Dr. Bogan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Axsome. Dr. Bogan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Idorsia. Dr. Bogan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Jazz. The institution of Dr. Bogan has received research support from Jazz Pharmaceuticals. The institution of Dr. Bogan has received research support from Harmony . The institution of Dr. Bogan has received research support from Eisai. The institution of Dr. Bogan has received research support from Avadel. The institution of Dr. Bogan has received research support from Takeda. The institution of Dr. Bogan has received research support from Suven. The institution of Dr. Bogan has received research support from Axsome. The institution of Dr. Bogan has received research support from Merck. The institution of Dr. Bogan has received research support from Liva Nova. The institution of Dr. Bogan has received research support from Nyxoah. Dr. Bogan has received research support from Bayer. The institution of Dr. Bogan has received research support from ZIO. The institution of Dr. Bogan has received research support from NLS. Dr. Bogan has received intellectual property interests from a discovery or technology relating to health care.
Michael J. Thorpy, MD (Montefiore Medical Center) Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz. Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avadel. Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for alkermes. Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Harmony. Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for centessa. Dr. Thorpy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Thorpy has received publishing royalties from a publication relating to health care.
No disclosure on file
Roman Skowronski, MD, PhD Dr. Skowronski has nothing to disclose.
Yves Dauvilliers, MD, PhD (Hopital Gui De Chaulliac) Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for idorsia. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for JAZZ. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Yves Dauvilliers, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avadel.